A Phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0,5 % and 2 % in adolescents with mild to moderate atopic dermatitis - Stein Fold, L F; Spelman, L; Spellman, M C (J Drugs Dermatol, 2016)
et al.